BG106867A - Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases - Google Patents

Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases

Info

Publication number
BG106867A
BG106867A BG106867A BG10686702A BG106867A BG 106867 A BG106867 A BG 106867A BG 106867 A BG106867 A BG 106867A BG 10686702 A BG10686702 A BG 10686702A BG 106867 A BG106867 A BG 106867A
Authority
BG
Bulgaria
Prior art keywords
vla
respiratory diseases
cell binding
dependent cell
treating inflammatory
Prior art date
Application number
BG106867A
Other languages
Bulgarian (bg)
English (en)
Inventor
Louis CHUPAK
Allen DUPLANTIER
Wan LAU
Anthony MILICI
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106867A publication Critical patent/BG106867A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG106867A 1999-12-28 2002-06-24 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases BG106867A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17326099P 1999-12-28 1999-12-28
PCT/IB2000/001893 WO2001051487A1 (en) 1999-12-28 2000-12-15 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases

Publications (1)

Publication Number Publication Date
BG106867A true BG106867A (en) 2003-02-28

Family

ID=22631221

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106867A BG106867A (en) 1999-12-28 2002-06-24 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases

Country Status (35)

Country Link
US (4) US20020049236A1 (cs)
EP (1) EP1244656A1 (cs)
JP (1) JP2003519697A (cs)
KR (1) KR20020067050A (cs)
CN (1) CN1413210A (cs)
AP (1) AP2002002565A0 (cs)
AR (1) AR029216A1 (cs)
AU (1) AU2018301A (cs)
BG (1) BG106867A (cs)
BR (1) BR0016818A (cs)
CA (1) CA2396087A1 (cs)
CO (1) CO5261616A1 (cs)
CR (1) CR6682A (cs)
CZ (1) CZ20022072A3 (cs)
EA (1) EA004673B1 (cs)
EE (1) EE200200372A (cs)
GT (1) GT200000226A (cs)
HU (1) HUP0203897A3 (cs)
IL (1) IL149758A0 (cs)
IS (1) IS6382A (cs)
MA (1) MA26861A1 (cs)
NO (1) NO20023085L (cs)
NZ (1) NZ518886A (cs)
OA (1) OA12126A (cs)
PA (1) PA8509301A1 (cs)
PE (1) PE20010987A1 (cs)
PL (1) PL357109A1 (cs)
SK (1) SK8692002A3 (cs)
SV (1) SV2002000246A (cs)
TN (1) TNSN00256A1 (cs)
TR (1) TR200201668T2 (cs)
UY (1) UY26512A1 (cs)
WO (1) WO2001051487A1 (cs)
YU (1) YU41202A (cs)
ZA (1) ZA200205142B (cs)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004673B1 (ru) * 1999-12-28 2004-06-24 Пфайзер Продактс Инк. Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
TWI312779B (cs) * 2000-12-28 2009-08-01 Daiichi Seiyaku Co
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
CA2528586A1 (en) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
US20050192279A1 (en) * 2004-02-10 2005-09-01 Kent Barbay Pyridazinones as antagonists of alpha4 integrins
CN1946699A (zh) * 2004-02-10 2007-04-11 詹森药业有限公司 作为α4整联蛋白拮抗剂的哒嗪酮脲类
PL1718608T3 (pl) 2004-02-20 2013-11-29 Boehringer Ingelheim Int Inhibitory polimerazy wirusowej
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006044412A1 (en) * 2004-10-12 2006-04-27 Amgen Inc. Novel b1 bradykinin receptor antagonists
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
EP1898940A4 (en) * 2005-06-07 2010-05-26 Univ Pennsylvania Alpha2beta1 / GPIa IIA INTEGRIN INHIBITORS
US8987306B2 (en) * 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US8129366B2 (en) 2005-12-13 2012-03-06 Daiichi Sankyo Company, Limited VLA-4 inhibitory drug
DK1984344T3 (da) 2005-12-29 2013-01-14 Lexicon Pharmaceuticals Inc Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
JP5847188B2 (ja) 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法
US9340500B2 (en) 2011-04-20 2016-05-17 Shionogi & Co., Ltd. Aromatic heterocyclic derivative having TRPV4-inhibiting activity
CA2839703A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
CA2839699A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
CN102268067A (zh) * 2011-06-29 2011-12-07 河北师范大学 一种含ldv序列短肽的聚乙二醇化衍生物
EP2769222A1 (en) 2011-10-17 2014-08-27 Westfälische Wilhelms-Universität Münster Methods of risk assessment of pml and related apparatus
CA2857344C (en) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
KR102122357B1 (ko) 2012-08-28 2020-06-15 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
ES2695182T3 (es) 2013-05-17 2019-01-02 Janssen Sciences Ireland Uc Derivados de sulfamoil tiofenamida y su uso como medicamentos para tratar la hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP3357906B1 (en) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
MX2017000087A (es) * 2014-06-30 2017-08-16 Uab Res Found Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
JP2019511542A (ja) 2016-04-15 2019-04-25 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合阻害剤を含む組み合わせ及び方法
JP2021515769A (ja) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤の投薬レジメン
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
WO2021150985A1 (en) 2020-01-22 2021-07-29 Seelos Therapeutics, Inc. Reducing side effects of nmda antagonists
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
AU646966B2 (en) 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU2958195A (en) 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
ATE237342T1 (de) 1994-07-11 2003-05-15 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
SG158733A1 (en) * 1996-07-25 2010-02-26 Biogen Idec Inc Cell adhesion inhibitors
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
WO1998053818A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1017382B1 (en) 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
WO1998054207A1 (en) 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
EP0991619B1 (en) 1997-06-23 2003-09-10 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha 4-beta 1 mediated cell adhesion
AR016387A1 (es) 1997-07-31 2001-07-04 Athena Neurosciences Inc Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos
CN1265675A (zh) 1997-07-31 2000-09-06 伊兰药品公司 抑制由vla－4介导的白细胞粘着的苄基化合物
HUP0002495A3 (en) 1997-07-31 2001-01-29 American Home Prod Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
AU756696B2 (en) 1997-07-31 2003-01-23 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
EP0994896A1 (en) 1997-07-31 2000-04-26 Elan Pharmaceuticals, Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
HUP0004529A3 (en) 1997-07-31 2001-05-28 American Home Prod Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
DE69834642T2 (de) 1997-07-31 2007-05-03 Elan Pharmaceuticals, Inc., South San Francisco Verbindungen mit einer 4-amino-phenylalaningruppe, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
PT1005446E (pt) 1997-08-22 2004-06-30 Hoffmann La Roche Derivados de n-aroilfenilalanina
DE69824183T2 (de) 1997-08-22 2005-04-21 Hoffmann La Roche N-alkanoylphenylalaninderivate
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU1361499A (en) 1997-10-21 1999-05-10 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
KR20010031557A (ko) * 1997-10-31 2001-04-16 추후제출 치환 아닐리드
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
WO1999025685A1 (en) * 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999026923A1 (en) 1997-11-20 1999-06-03 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
EP1033983A1 (en) 1997-11-24 2000-09-13 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
EP1034164B1 (en) 1997-11-24 2004-05-19 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
DE69829215T2 (de) * 1997-12-23 2005-07-21 Aventis Pharma Ltd., West Malling Substituierte beta-alaninen
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
WO1999037605A1 (en) * 1998-01-23 1999-07-29 Novartis Ag Vla-4 antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002504534A (ja) 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α４インテグリンの阻害剤としてのフェニルアラニン誘導体
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
AU3748399A (en) 1998-04-16 1999-11-01 Texas Biotechnology Corporation N,n-disubstituted amides that inhibit the binding of integrins to their receptors
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
MXPA00011774A (es) 1998-05-28 2002-10-17 Biogen Inc Un nuevo inhibidor vla-4: ome pupa-v.
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
WO1999064395A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
SK20052000A3 (sk) * 1998-06-30 2002-08-06 Pfizer Products Inc. Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
AU1915399A (en) 1998-07-10 2000-02-01 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
EP1133484A2 (en) 1998-07-23 2001-09-19 AstraZeneca AB Heterocyclic derivatives and their use as integrin inhibitors
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
SK2612001A3 (en) 1998-08-26 2001-11-06 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9821406D0 (en) 1998-10-01 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CA2351464A1 (en) 1998-12-14 2000-06-22 Joan E. Sabalski 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
US6545003B1 (en) 1999-01-22 2003-04-08 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
US6465513B1 (en) 1999-01-22 2002-10-15 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
AU2623900A (en) 1999-01-22 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
EA004673B1 (ru) 1999-12-28 2004-06-24 Пфайзер Продактс Инк. Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний

Also Published As

Publication number Publication date
US6668527B2 (en) 2003-12-30
WO2001051487A1 (en) 2001-07-19
TNSN00256A1 (fr) 2002-05-30
KR20020067050A (ko) 2002-08-21
PE20010987A1 (es) 2001-10-02
NO20023085D0 (no) 2002-06-26
HUP0203897A3 (en) 2005-06-28
NO20023085L (no) 2002-06-26
US6903128B2 (en) 2005-06-07
AP2002002565A0 (en) 2002-06-30
YU41202A (sh) 2005-03-15
CO5261616A1 (es) 2003-03-31
PL357109A1 (en) 2004-07-12
IS6382A (is) 2002-05-14
CN1413210A (zh) 2003-04-23
HUP0203897A2 (hu) 2003-03-28
US20020049236A1 (en) 2002-04-25
CA2396087A1 (en) 2001-07-19
AR029216A1 (es) 2003-06-18
EP1244656A1 (en) 2002-10-02
CZ20022072A3 (cs) 2003-05-14
US20030004196A1 (en) 2003-01-02
OA12126A (en) 2006-05-05
SV2002000246A (es) 2002-07-16
US6667331B2 (en) 2003-12-23
BR0016818A (pt) 2002-10-01
SK8692002A3 (en) 2003-06-03
US20040102496A1 (en) 2004-05-27
EA004673B1 (ru) 2004-06-24
PA8509301A1 (es) 2002-12-11
MA26861A1 (fr) 2004-12-20
US20030100585A1 (en) 2003-05-29
CR6682A (es) 2004-01-14
IL149758A0 (en) 2002-11-10
EE200200372A (et) 2003-12-15
EA200200619A1 (ru) 2002-10-31
AU2018301A (en) 2001-07-24
TR200201668T2 (tr) 2002-11-21
ZA200205142B (en) 2003-09-29
JP2003519697A (ja) 2003-06-24
UY26512A1 (es) 2001-07-31
GT200000226A (es) 2002-06-20
NZ518886A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
NO20012567L (no) Azepinoindolderivater, fremstilling og anvendelse derav
JO2282B1 (en) Oxazole derivatives
NO20003018D0 (no) Triazinangiogenese-inhibitorer
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
IS6852A (is) Efnasambönd
MY138797A (en) Bacterial gyrase inhibitors and uses thereof
BG106585A (en) Kinase inhibitors as therapeutic agents
ATE440603T1 (de) 8-hydroxychinolinderivate
MY138140A (en) N-aroylphenylalanine derivatives
MY126972A (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
EA200701504A1 (ru) Индолы, пригодные для лечения воспалений
MY138352A (en) Benzothiazole derivatives
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
MXPA04005809A (es) Inhibidores de proteinas quinasas.
TW200510372A (en) Novel amides useful for treating pain
TR200102395T2 (tr) Fenilalaninol türevleri.
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
SE0004827D0 (sv) Therapeutic compounds
DE60117783D1 (de) Naphthamidin-urokinasinhibitoren
NO20042729L (no) Heksasykliske forbindelser